KMID : 1161420160190020133
|
|
Journal of Medicinal Food 2016 Volume.19 No. 2 p.133 ~ p.140
|
|
Purslane Extract and Glucose Homeostasis in Adults with Type 2 Diabetes: A Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety
|
|
Wainstein Julio
Landau Zohar Dayan Yosefa Bar Jakubowicz Daniela Grothe Torsten Perrinjaquet-Moccetti Tania Boaz Mona
|
|
Abstract
|
|
|
Purslane extract (PE) is derived from Portulaca oleracea L., a medicinal plant used in traditional medicine for its antidiabetic properties. This randomized, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of PE in improving glucose control, blood pressure, and lipid profile in adults with type 2 diabetes mellitus (T2DM) treated with a single oral hypoglycemic agent at baseline. Subjects were randomized to treatment with three capsules of PE/day or a matched placebo. Change from baseline to the week 12 end-of-follow-up visit measures of glucose homeostasis, hemodynamics, and lipid profile was compared by treatment assignment. In addition, these measures were evaluated in a subgroup of ¡°responders,¡± defined as patients whose week 12 HbA1c was lower than baseline values, regardless of treatment assignment. This group was further assessed in subgroups of baseline oral hypoglycemic treatment. A total of 63 participants were treated with either PE (n?=?31, 11 females, mean age 52.4?¡¾?7.9 years) or matched placebo (n?=?32, 11 females, mean age 58.3?¡¾?10.8 years). In the total cohort, systolic blood pressure declined significantly more in the PE group than the placebo group: ?7.5?¡¾?5.0 versus ?0.01?¡¾?0.3?mmHg, P?.0001. In the responders' subgroup, HbA1c declined significantly more in the PE group than the placebo group: ?0.8%?¡¾?0.4% versus ?0.6%?¡¾?0.5%, P?=?.03. Few adverse events were reported. These were mild and did not differ by treatment assignment. PE appears to be a safe, adjunct treatment for T2DM, significantly reducing systolic blood pressure in the total cohort and HbA1c in the subgroup of responders.
|
|
KEYWORD
|
|
purslane, randomized clinical trial, type 2 diabetes
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|